Comparing efficacy and safty of three dose-regulating protocol of glargine in hospitalized diabetic patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12001916

Enrollment

Unknown

Registered

2012-02-01

Start date

2011-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

"2-8" group:increase glargine dose "2U-8U" based on the fasting glugose level

“20%” group:increase glargine dose 20% of present dose

“0.1”group:increase glargine dose 0.1U/kg body weight

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Hospitalized type 2 diabetes; 2. 18~75 years;

Exclusion criteria

Exclusion criteria: 1. Diabetes other than type 2 diabetes mellitus; 2. Age 75years; 3. Hepatic or renal dysfucion; 4. Any contraindication to use of insulin glargine as defined in the national product label; 5. Unconsciousness.

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose;	—

Countries

China

Contacts

Public ContactLi Wan-gen

liwg660@126.com+86 13500031715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026